Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Revenue: 2020-2025

Historic Revenue for Pharming Group N.V (PHAR) over the last 4 years, with Sep 2025 value amounting to $97.3 million.

  • Pharming Group N.V's Revenue rose 29.98% to $97.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.8 million, marking a year-over-year decrease of 7.67%. This contributed to the annual value of $297.2 million for FY2024, which is 21.15% up from last year.
  • According to the latest figures from Q3 2025, Pharming Group N.V's Revenue is $97.3 million, which was up 10,139.94% from -$969,000 recorded in Q2 2025.
  • Pharming Group N.V's Revenue's 5-year high stood at $198.7 million during Q4 2021, with a 5-year trough of -$93.1 million in Q3 2021.
  • Over the past 3 years, Pharming Group N.V's median Revenue value was $70.4 million (recorded in 2023), while the average stood at $63.9 million.
  • Per our database at Business Quant, Pharming Group N.V's Revenue slumped by 272.24% in 2021 and then spiked by 106,908.08% in 2022.
  • Over the past 5 years, Pharming Group N.V's Revenue (Quarterly) stood at $198.7 million in 2021, then tumbled by 72.51% to $54.6 million in 2022, then skyrocketed by 48.69% to $81.2 million in 2023, then grew by 14.10% to $92.7 million in 2024, then grew by 29.98% to $97.3 million in 2025.
  • Its Revenue stands at $97.3 million for Q3 2025, versus -$969,000 for Q2 2025 and $92.7 million for Q4 2024.